During this segment, the panelists conclude that although treatment guidelines are now being developed to help practitioners consider therapy options for patients with systemic lupus erythematosus (SLE), there are still factors that need to be addressed.
Michelle Petri, MD, MPH, explains that there are now 3 clinical practice guidelines for the treatment of lupus, whereas in the past there were none. The American College of Rheumatology, Systemic Lupus International Collaborating Clinics, and European League Against Rheumatism guidelines exhibit consistencies about how to treat patients with lupus.
However, Dr Petri explains that the guidelines need to address how to treat patients who fail suggested induction therapies. Dr Petri believes that flexibility is key due to the need to individualize therapy for patients in instances of poor outcomes.
Dr Petri feels that our country is still in the “dark ages” in regard to addressing the needs of patients with SLE. She explains that because SLE is a rare disease, there is still no FDA-approved gold standard for treating the disease.
Agreeing with Dr Petri, Maria Lopes, MD, MS, believes that there is a need for personalized therapy, which requires an in-depth, collaborative discussion about how to treat a patient as an individual before beginning therapy.
Report Reveals Mounting Burdens of Drug Shortages on US Health System
June 27th 2025Vizient's 2024 survey reveals a sharp rise in drug shortages across US health care, with pediatric care hit especially hard and labor costs soaring—but the true impact may go far beyond limited medication access, threatening to disrupt the very foundations of how health systems operate.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen